Irvine, Calif.-based Axonics, which makes the r-SNM device sacral neuromodulation system for treating overactive bladder, fecal incontinence and urinary retention, had set the range for the flotation at $93.3 million to $106.7 million, but later increased the number of shares to 8 million, priced at $15 each.
The 30-day, 1.2-million-share over-allotment, if fully exercised, would add $18 million to the IPO’s gross.
Axonics touts the r-SNM device as the first such rechargeable system; it’s designed to deliver mild electrical stimulation using a four-electrode lead introduced through the sacrum and a pulse generator implanted in the upped buttocks. It won CE Mark approval in the European Union in June 2016; an external trial module won an FDA nod last July. It’s also approved for market in Canada and Australia. In its initial IPO filing, Axonics said it expects to file a pre-market approval bid with the FDA during the first quarter of 2019.
BofA Merrill Lynch and Morgan Stanley were joint book-runners, with Wells Fargo Securities as lead manager and SunTrust Robinson Humphrey as co-manager, Axonics said.
AXNX shares opened at $16.05 apiece on Oct. 31 before closing down -6.7% at $14.98. The stock was trading at $15.12 per share today in mid-day activity, up 4.3%.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.